Literature DB >> 17109719

Prescription pattern of antipsychotic drugs for schizophrenic inpatients in Japan: research on East Asia Psychotropic Prescription Pattern-Antipsychotics study.

Reiji Yoshimura, Tatsuya Okamoto, Jun Nakamura, Masaru Tateno, Kotaro Otsuka, Hidehiko Takahashi, Daisuke Fujisawa, Toko Takamatsu, Senta Fujii, Soichiro Sato, Masayuki Inoue, Hiromitsu Sasaki, Toshihide Kuroki, Naotaka Shinfuku.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17109719     DOI： 10.1111/j.1440-1819.2006.01601.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN： 1323-1316            Impact factor:   5.188


× No keyword cloud information.
  5 in total

Review 1.  Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Authors:  Thomas R E Barnes; Carol Paton
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

2.  Analysis of the trends of polypharmacy and high-dose prescriptions in Japan.

Authors:  Naotaka Shinfuku
Journal:  Asia Pac Psychiatry       Date:  2021-09-14       Impact factor: 3.788

3.  Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study.

Authors:  Michihiro Takahashi; Naohiro Nakahara; Shinji Fujikoshi; Masaomi Iyo
Journal:  Pragmat Obs Res       Date:  2015-07-14

4.  Patterns of prescription of antipsychotics in Qatar.

Authors:  Sami Ouanes; Imen Becetti; Suhaila Ghuloum; Samer Hammoudeh; Mena Shehata; Hany Ghabrash; Areej Yehya; Hawra Al-Lawati; Nora Al-Fakhri; Huma Iram; Nighat Ajmal; Yassin Eltorki; Hassen Al-Amin
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

5.  Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis.

Authors:  Wenyu Ye; Haya Ascher-Svanum; Yuka Tanji; Jennifer A Flynn; Michihiro Takahashi; Robert R Conley
Journal:  Neuropsychiatr Dis Treat       Date:  2012-06-18       Impact factor: 2.570
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.